[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Article
  • Published:

Phase I–II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas

Gene Therapy volume 12, pages 437–445 (2005)Cite this article

Abstract

ONYX-015 is a provisionally replication competent adenovirus with oncolytic activity in cells with malfunctioning p53. Sarcomas represent a rational target for this approach given the high frequency of p53 mutations (40–75%) and MDM-2 amplification (10–30%). We, therefore, undertook a phase I/II study of ONYX-015, days 1–5 every month administered intratumorally under radiographic guidance, in combination with MAP (mitomycin-C, doxorubicin, cisplatin) chemotherapy in patients with advanced sarcoma. Six patients were treated. Injected lesions included liver metastases in four patients and chest wall metastases in two patients. Sarcoma histologies were gastrointestinal stromal tumors (GIST, two patients), leiomyosarcoma (two patients), liposarcoma (one patient), and malignant peripheral nerve sheath tumor (1 patient). Dose escalation was performed from 109 plaque forming units (PFU)/dose (total dose of 5 × 109 PFU/cycle) to 1010 PFU/dose (total dose of 5 × 1010 PFU/cycle) without dose-limiting toxicity being encountered. Immunohistochemistry of the metastatic lesions prior to treatment showed that five out of six patients were positive for p53, while two patients also had mdm-2 overexpression. Adenoviral replication was detected in two out of six patient biopsies on day 5 of the first cycle, by in situ hybridization (ISH). Both patients were treated at the highest dose level. ONYX-015 viral DNA was detected by quantitative PCR in the plasma of 5/6 patients on day 5 of the first cycle, and up to day 12 (7 days after the last viral dose) in one patient who had extended sampling for viral kinetics performed, suggesting viral replication in sarcoma tissue. One patient with p53 mutation and MDM-2 amplification achieved a partial response to treatment that lasted 11 months. In conclusion, intratumoral administration of ONYX-015 in combination with MAP chemotherapy is well tolerated with no significant toxicity due to ONYX-015 being encountered. Detection of viral DNA in post treatment tumor specimens by ISH and detection of the ONYX-015 genome in the peripheral blood by quantitative PCR, up to 7 days after the last viral dose provide evidence for adenoviral replication. There was evidence of antitumor activity in one out of six patients. Further investigation of this approach in patients with recurrent sarcomas is warranted.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Barker DD, Berk AJ . Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 1987; 156: 107–121.

    Article  CAS  PubMed  Google Scholar 

  2. Dobner T, Horikoshi N, Rubsenwolf S, Shenk T . Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science (Wash. DC) 1996; 272: 1470–1473.

    Article  CAS  Google Scholar 

  3. Bischoff JR et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (Wash. DC) 1996; 274: 373–376.

    Article  CAS  Google Scholar 

  4. Harada J, Berk A . p53-independent and -dependent requirements for E1B-55 kD in adenovirus type 5 replication. J Virol 1999; 73: 5333–5344.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Rothmann T et al. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 1998; 72: 9470–9478.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Goodrum FD, Ornelles DA . P53 status does not determine outcome in E1B 55-kilodalton mutant adenovirus lytic infection. J Virol 1998; 72: 9479–9490.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Rogulski K et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res 2000; 60: 1193–1196.

    CAS  PubMed  Google Scholar 

  8. Heise C et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolosis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3: 639–645.

    Article  CAS  PubMed  Google Scholar 

  9. Heise C et al. Preclinical studies with ONYX-015 (a replication competent E1B-deleted adenovirus) in combination with chemotherapy. Cancer Gene Ther 1997; 4: S13.

    Google Scholar 

  10. Kirn D et al. ONYX-015, a selectively replicating E1B-deleted adenovirus, has significant activity against human ovarian carcinoma alone and in combination with standard chemotherapeutic agents. Proc ASCO 1998; 17: 211a.

    Google Scholar 

  11. Khuri FR et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879–885.

    Article  CAS  PubMed  Google Scholar 

  12. Hecht JR et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003; 9: 555–561.

    CAS  PubMed  Google Scholar 

  13. Reid T et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002; 62: 6070–6079.

    CAS  PubMed  Google Scholar 

  14. Hamid O et al. Phase II trial of intravenous CI-1402 in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 1498–1504.

    Article  CAS  PubMed  Google Scholar 

  15. Vasey PA et al. Phase I trial of intraperitoneal injection of the E1B-55 kD-gene deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002; 20: 1562–1569.

    CAS  PubMed  Google Scholar 

  16. Saeter G et al. Prognostic factors in bone sarcomas. Acta Orthop Scand Suppl 1997; 273: 156–160.

    Article  CAS  PubMed  Google Scholar 

  17. Edmonson JH et al. Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas. Cancer Chemother Pharmacol 1985; 15: 181–182.

    Article  CAS  PubMed  Google Scholar 

  18. Saeter G . Chemotherapy for adult soft tissue sarcoma. Does it work? Acta Orthop Scand Suppl 1997; 273: 139–144.

    Article  CAS  PubMed  Google Scholar 

  19. Hung J, Anderson R . p53: functions, mutations and sarcomas. Acta Orthop Scand Suppl 1997; 273: 68–73.

    Article  CAS  PubMed  Google Scholar 

  20. Seki A et al. Amplification of the mdm-2 gene and p53 abnormalities in uterine sarcomas. Int J Cancer 1997; 73: 33–37.

    Article  CAS  PubMed  Google Scholar 

  21. Edmonson JH et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11: 1269–1275.

    Article  CAS  PubMed  Google Scholar 

  22. Galanis E et al. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: a phase I/II experience. J Clin Oncol 1999; 17: 3313–3323.

    Article  CAS  PubMed  Google Scholar 

  23. Nemunaitis J et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biologic activity. Gene Therapy 2001; 8: 746–759.

    Article  CAS  PubMed  Google Scholar 

  24. Peng KW et al. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 2002; 62: 4656–4662.

    CAS  PubMed  Google Scholar 

  25. Peng KW et al. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med 2002; 8: 527–531.

    Article  CAS  PubMed  Google Scholar 

  26. Phuong LK et al. Use of a vaccine strain of measles virus genetically engineered to produce CEA as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 2003; 63: 2462–2469.

    CAS  PubMed  Google Scholar 

  27. Galanis E, Cattaneo R, Sloan J . Discussion of human gene transfer protocol #0201-523: phase I trial of intraperitoneal administration of an attenuated strain (Edmonston strain) of measles virus, genetically engineered to produce carcinoembryonic antigen, in patients with recurrent ovarian cancer. Recombinant DNA Advisory Committee. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health Minutes of Meeting, June 20–21, 2002. Hum Gene Ther 2002; 13: 2219–2239.

    Article  Google Scholar 

  28. Nemunaitis J et al. Selective replication and oncolysis in p53 mutant tumors with Onyx-015, an E1B-55 kD gene-deleted adenovirus, in patients with head and neck cancer. Cancer Res 2000; 60: 6359–6366.

    CAS  PubMed  Google Scholar 

  29. Mulvihill S et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Therapy 2001; 8: 308–315.

    Article  CAS  PubMed  Google Scholar 

  30. Benjamin R et al. A phase I/II dose escalation and activity study of intravenous injections of OcaP1 for subjects with refractory osteosarcoma metastatic to lung. Hum Gene Ther 2001; 12: 1591–1593.

    CAS  PubMed  Google Scholar 

  31. Simon R et al. Acclerated titration design for phase I clinical trials in oncology. J Natl Cancer Inst 1997; 89: 1138–1147.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We acknowledge Dr David Kirn for helpful input, Ms Deb Sprau for coordinating patient care, and Ms Raquel Ostby for her help with preparation of the manuscript. This study was supported through CA 84388 (EG), UO1CA 69912, and Mayo Clinic General Clinical Research Center (GCRC) Grant R00585.

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA

    E Galanis, S H Okuno, J H Edmonson, C Erlichman & J Rubin

  2. Department of Pathology, Mayo Clinic, Rochester, MN, USA

    A G Nascimento & A M Oliveira

  3. Department of Radiology, Mayo Clinic, Rochester, MN, USA

    B D Lewis & R A Lee

  4. Department of Biostatistics, Mayo Clinic, Rochester, MN, USA

    J A Sloan & P Atherton

  5. Onyx Pharmaceuticals, Inc., Richmond, CA, USA

    B Randlev, Q Wang & S Freeman

Authors
  1. E Galanis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S H Okuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A G Nascimento
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B D Lewis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R A Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A M Oliveira
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J A Sloan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P Atherton
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J H Edmonson
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C Erlichman
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. B Randlev
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Q Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. S Freeman
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. J Rubin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Galanis, E., Okuno, S., Nascimento, A. et al. Phase I–II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther 12, 437–445 (2005). https://doi.org/10.1038/sj.gt.3302436

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302436

Keywords

This article is cited by

Search

Advanced search

Quick links